Endometrial cancer.
Despite the questions and barriers, the incorporation of molecular therapy into treatment regimens in endometrial cancer is an exciting area of investigation with the potential to improve outcomes. Outside of the development of a reliable screening test for endometrial cancer, converting the disease to a chronic state and improving progression-free survival is our best hope to reverse the concerning trend of decreasing 5-year survival for this disease.
Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. kimberly-leslie@uiowa.edu
Kimberly K
KK
Leslie
Kristina W
KW
Thiel
Michael J
MJ
Goodheart
Koen
K
De Geest
Yichen
Y
Jia
Shujie
S
Yang
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008197:Lymph Node Excision; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D009765:Obesity / Q000150:complications; D017698:Postmenopause; D011379:Prognosis; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D014592:Uterine Hemorrhage / Q000209:etiology